SEC Filing Summary: Frequency Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on March 26, 2020. The filing serves as a current report announcing the Company's financial results and operational updates for the quarter and full year ended December 31, 2019. The detailed financial data is contained within the press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms that results for the 2019 period were announced.
Guidance, Outlook, and Risks
The Company provided operational updates alongside the financial results. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to the liabilities of Section 18 of the Exchange Act. No specific guidance, risk factors, or unusual items are detailed in the cover text.
Investor Verification Checklist
- Verify the correct registrant name is Frequency Therapeutics, Inc. (Ticker: FREQ), as the input metadata incorrectly listed "Korro Bio, Inc."
- Review Exhibit 99.1 (Press Release) for actual financial figures, as they are absent from the 8-K cover sheet.
- Confirm the status of the "furnished" information regarding legal liability and incorporation by reference.
- Check the operational updates mentioned in the press release for context on the 2019 performance.